1,148 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Capula Management Ltd

Capula Management Ltd bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,148 shares of the biopharmaceutical company's stock, valued at approximately $354,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MDGL. Renaissance Technologies LLC raised its position in Madrigal Pharmaceuticals by 261.3% in the fourth quarter. Renaissance Technologies LLC now owns 160,782 shares of the biopharmaceutical company's stock valued at $49,613,000 after purchasing an additional 116,285 shares during the period. Invesco Ltd. grew its stake in shares of Madrigal Pharmaceuticals by 7.3% in the fourth quarter. Invesco Ltd. now owns 129,074 shares of the biopharmaceutical company's stock valued at $39,828,000 after buying an additional 8,828 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter valued at about $453,000. FMR LLC lifted its position in Madrigal Pharmaceuticals by 10.8% during the 4th quarter. FMR LLC now owns 867,850 shares of the biopharmaceutical company's stock worth $267,792,000 after acquiring an additional 84,305 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Madrigal Pharmaceuticals by 120.2% in the 4th quarter. Russell Investments Group Ltd. now owns 1,482 shares of the biopharmaceutical company's stock worth $457,000 after acquiring an additional 809 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, Director James M. Daly sold 15,470 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $347.45, for a total transaction of $5,375,051.50. Following the transaction, the director now owns 1,912 shares of the company's stock, valued at approximately $664,324.40. This trade represents a 89.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Rebecca Taub sold 1,689 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $273.41, for a total transaction of $461,789.49. Following the completion of the transaction, the chief marketing officer now owns 457,310 shares of the company's stock, valued at $125,033,127.10. This trade represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,900 shares of company stock worth $12,168,079. Insiders own 22.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Citigroup lifted their price target on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Finally, B. Riley upgraded Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and raised their target price for the company from $236.00 to $422.00 in a research note on Thursday, February 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $378.44.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL traded up $9.80 during trading hours on Friday, reaching $317.15. 390,555 shares of the stock were exchanged, compared to its average volume of 392,846. The stock has a market capitalization of $7.00 billion, a P/E ratio of -12.65 and a beta of -0.69. The firm has a 50 day simple moving average of $331.33 and a 200-day simple moving average of $304.37. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals, Inc. has a 52 week low of $189.00 and a 52 week high of $377.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.32) by $1.61. The firm had revenue of $103.32 million for the quarter, compared to the consensus estimate of $97.81 million. As a group, sell-side analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.